128 related articles for article (PubMed ID: 38432025)
1. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
Chul Cho B; Han JY; Hyeong Lee K; Lee YG; Kim DW; Joo Min Y; Kim SW; Kyung Cho E; Kim JH; Lee GW; Sook Lee S; Lee N; Young Wang J; Park H; Ahn MJ
Lung Cancer; 2024 Apr; 190():107509. PubMed ID: 38432025
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
3. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Lee KH; Cho BC; Ahn MJ; Lee YG; Lee Y; Lee JS; Kim JH; Min YJ; Lee GW; Lee SS; Lee KH; Ko YH; Shim BY; Kim SW; Shin SW; Choi JH; Kim DW; Cho EK; Park KU; Kim JS; Chun SH; Wang J; Choi S; Kang JH
Cancer Res Treat; 2024 Jan; 56(1):48-60. PubMed ID: 37402411
[TBL] [Abstract][Full Text] [Related]
4. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
[TBL] [Abstract][Full Text] [Related]
5. Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.
Kim H; Ahn BC; Lee J; Lee JB; Hong MH; Kim HR; Cho BC; Lim SM
Lung Cancer; 2023 Jun; 180():107213. PubMed ID: 37104879
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
7. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
[TBL] [Abstract][Full Text] [Related]
8. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With
Cho BC; Ahn MJ; Kang JH; Soo RA; Reungwetwattana T; Yang JC; Cicin I; Kim DW; Wu YL; Lu S; Lee KH; Pang YK; Zimina A; Fong CH; Poddubskaya E; Sezer A; How SH; Danchaivijitr P; Kim Y; Lim Y; An T; Lee H; Byun HM; Zaric B
J Clin Oncol; 2023 Sep; 41(26):4208-4217. PubMed ID: 37379502
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
11. Lazertinib: First Approval.
Dhillon S
Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
[TBL] [Abstract][Full Text] [Related]
12. Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Reungwetwattana T; Cho BC; Lee KH; Pang YK; Fong CH; Kang JH; Lee YG; Lim CS; Danchaivijitr P; Lim YN; Lee Y; How SH; Geater S; Lee SS; Min YJ; Kim JH; Lee JS; Lee GW; Soo RA; Lee SY; Choi S; Ahn MJ
J Thorac Oncol; 2023 Oct; 18(10):1351-1361. PubMed ID: 37702629
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
14. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
Mok T; Nakagawa K; Park K; Ohe Y; Girard N; Kim HR; Wu YL; Gainor J; Lee SH; Chiu CH; Kim SW; Yang CT; Wu CL; Wu L; Lin MC; Samol J; Ichikado K; Wang M; Zhang X; Sylvester J; Li S; Forslund A; Yang JC
J Clin Oncol; 2024 Apr; 42(11):1252-1264. PubMed ID: 38252907
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.
Lee B; Ji W; Lee JC; Song SY; Shin YS; Cho YH; Park JE; Park H; Choi CM
Thorac Cancer; 2023 Aug; 14(22):2233-2237. PubMed ID: 37365915
[TBL] [Abstract][Full Text] [Related]
18. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
19. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
[TBL] [Abstract][Full Text] [Related]
20. Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
Shi Y; Zhou J; Zhao Y; Zhu B; Zhang L; Li X; Fang J; Shi J; Zhuang Z; Yang S; Wang D; Yu H; Zhang L; Zheng R; Greco M; Wang T
BMC Med; 2023 Jan; 21(1):11. PubMed ID: 36617560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
